Abstract 41P
Background
The importance of regulating and improving the tumor immune microenvironment is increasingly being recognized. While it has been reported that therapeutic agents for hyperlipidemia, in particular statins, can induce cancer cell growth suppression and anti-metastatic effects in breast cancer, few studies have investigated the correlation between improvement of lipid metabolism and antitumor immune response and cancer prognosis in vivo.
Methods
Except for patients with ductal carcinoma in situ, 938 breast cancer patients treated with curative surgery were examined. The correlation between serum levels of total-cholesterol and triglyceride, and clinicopathological features, including pre- and postoperative neutrophil-to-lymphocyte ratio (NLR) and tumor-infiltrating lymphocytes (TILs), and prognosis was evaluated retrospectively.
Results
194 patients were receiving treatment for hyperlipidemia. Recurrence-free survival (RFS) and overall survival (OS) did not differ significantly between users of the drug for hyperlipidemia or non-users (p = 0.782, log-rank) (p = 0.304, log-rank). Among postmenopausal patients with hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer, who were treated for hyperlipidemia, the group with good serum lipid control had significantly better RFS (p = 0.014, log-rank). Good serum lipid control was also significantly correlated with low postoperative NLR (p = 0.024). In addition, high-TILs in resected tissues was significantly associated with preoperative serum lipid levels (p = 0.039). In the drug type, lipophilic statin users had lower recurrence rate than hydrophilic statin users (8.2 % vs 16.0 %).
Conclusions
Good control of serum lipid metabolism may have a relationship with improvement of tumor immune microenvironment and favorable outcome in postmenopausal HR-positive/HER2-negative breast cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
155P - Mean Platelet Volume (MPV) is it a new prognostic marker in resectable carcinoma stomach?
Presenter: Girish M. S
Session: Poster display session
Resources:
Abstract
156P - A positive feedback between IDO1 metabolite and COL12A1 via MAPK pathway to promote gastric cancer metastasis
Presenter: Zhen Xiang
Session: Poster display session
Resources:
Abstract
157P - Lymph node ratio (LNR) a better prognostic factor after D2 gastrectomy
Presenter: Jitin Yadav
Session: Poster display session
Resources:
Abstract
158P - A clinical significance of preoperative C-reactive protein/albumin ratio in patients with extrahepatic bile duct cancer
Presenter: Kim Jinkook
Session: Poster display session
Resources:
Abstract
159P - The relation between obesity and cancer of gastrointestinal tract in Korea: The data from Statistic Korea between 2001 and 2016
Presenter: Hee Man Kim
Session: Poster display session
Resources:
Abstract
160P - Clinical outcomes of second-line chemotherapy after progression on nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma
Presenter: Jooyoung Ha
Session: Poster display session
Resources:
Abstract
161P - Chitinase 3-Like 1 gene (T/C) polymorphism and serum YKL-40 in hepatocellular carcinoma
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract
162P - Hypofractionated radiotherapy for pulmonary metastases from hepatocellular carcinoma: Treatment response and prognostic factors affecting survival
Presenter: In Young Jo
Session: Poster display session
Resources:
Abstract
163P - Excision repair cross-complementation group 1 and 2 (ERCC1/2) Single nucleotide polymorphisms and chemotherapy treatment outcome in Cholangiocarcinoma
Presenter: Thanachai Sanlung
Session: Poster display session
Resources:
Abstract
164P - Multi-centered phase II trial of weekly 5-FU plus l-LV regimen as salvage line chemotherapy for oral fluorouracil resistant advanced gastric cancer (HGCSG1502)
Presenter: Yusuke Sasaki
Session: Poster display session
Resources:
Abstract